Harrow, Inc. Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price
Harrow, Inc. (HROW) had Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price of $5.08 per share as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 · last filed 2026-03-02
- 2025-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $5.08.
- 2025-09-30: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $4.84.
- 2025-06-30: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $5.59.
- 2025-03-31: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $5.56.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price | Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price as first filed |
|---|---|---|
| 2025-12-31 | $5.08 10-K · filed 2026-03-02 | |
| 2025-09-30 | $4.84 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $5.59 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $5.56 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $5.52 10-K · filed 2025-03-27 | |
| 2024-09-30 | $5.50 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $5.62 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $5.55 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $5.55 10-K · filed 2024-03-19 | |
| 2023-09-30 | $5.51 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $5.50 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $5.73 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $5.51 10-K · filed 2023-03-23 | |
| 2022-09-30 | $5.33 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $5.32 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $5.29 10-Q · filed 2022-05-05 | |
| 2021-09-30 | $5.07 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $5.01 10-Q · filed 2021-08-10 | |
| 2021-03-31 | $4.85 10-Q · filed 2021-05-11 | |
| 2020-12-31 | $5.10 10-K · filed 2022-03-10 | $4.49 10-K · filed 2021-03-08 |
| 2020-09-30 | $4.45 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $4.53 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $4.52 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $4.57 10-K · filed 2020-03-13 | |
| 2019-09-30 | $4.62 10-Q · filed 2019-11-13 | |
| 2019-06-30 | $4.69 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $4.74 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $4.94 10-K · filed 2019-03-12 | |
| 2018-09-30 | $5.12 10-Q · filed 2018-11-13 | |
| 2018-06-30 | $5.56 10-Q · filed 2018-08-06 | |
| 2018-03-31 | $5.55 10-Q · filed 2018-05-15 | |
| 2017-12-31 | $5.74 10-K · filed 2018-03-08 | |
| 2017-09-30 | $5.90 10-Q · filed 2017-11-14 | |
| 2017-06-30 | $6.06 10-Q · filed 2017-08-10 | |
| 2017-03-31 | $6.29 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $6.18 10-K · filed 2017-03-21 | |
| 2016-09-30 | $6.26 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $6.34 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $6.36 10-Q · filed 2016-05-12 | |
| 2015-12-31 | $6.22 10-K · filed 2016-03-23 | |
| 2015-09-30 | $6.15 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $5.44 10-Q · filed 2015-08-12 | |
| 2015-03-31 | $5.40 10-Q · filed 2015-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |